Cancer

CURE Media Group announces Vanessa Bayer as keynote speaker for the 2022 MPN Heroes® Recognition Program 

Retrieved on: 
Friday, December 2, 2022

CRANBURY, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced Emmy-nominated actress, writer and comedian Vanessa Bayer as the keynote speaker of the 2022 MPN Heroes Recognition Program.

Key Points: 
  • CRANBURY, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients, survivors, and caregivers, today announced Emmy-nominated actress, writer and comedian Vanessa Bayer as the keynote speaker of the 2022 MPN Heroes Recognition Program.
  • We are truly delighted that Vanessa Bayer will join us to deliver the keynote address at this years MPN Heroes recognition ceremony, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of CURE Media Group.
  • The recipients of the 2022 MPN Heroes Recognition Program, who have made a significant impact in the MPN blood cancer community, will be announced at the event.
  • Incyte Corporation partners with CURE Media Group to support the program, with CURE hosting the annual MPN Heroes recognition ceremony.

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Friday, December 2, 2022

Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In-person and virtual meetings may be scheduled directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

Retrieved on: 
Friday, December 2, 2022

Webcast / Conference Call Information:

Key Points: 
  • Webcast / Conference Call Information:
    The conference call can be also accessed by dialing +1 929 205 6099 for participants in the U.S. using the Webinar ID: 815 1815 0021 reference passcode 279853.
  • A replay of the conference call will also be available on Anavexs website for up to 30 days.
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022

The awards were granted pursuant to terms and conditions fixed by the Compensation Committee and as an inducement material to each new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The awards were granted pursuant to terms and conditions fixed by the Compensation Committee and as an inducement material to each new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The option awards have an exercise price of $6.77 per share, which is equal to the closing price of Mersanas common stock on December 1, 2022.
  • Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe.
  • Mersana routinely posts information that may be useful to investors on the Investors & Media section of its website at www.mersana.com .

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 86,000 shares of its common stock to three employees outside Cullinan Oncology, Incs 2021 Stock Option and Incentive Plan.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 86,000 shares of its common stock to three employees outside Cullinan Oncology, Incs 2021 Stock Option and Incentive Plan.
  • The stock options were granted as an inducement material to the individuals entering into employment with Cullinan, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Cullinan Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer.
  • Learn more about our Company at www.cullinanoncology.com , and follow us on LinkedIn and Twitter .

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

Retrieved on: 
Friday, December 2, 2022

NKX019, a wholly owned program of Nkarta, is an investigational healthy donor-derived CAR NK cell therapy targeting CD19.

Key Points: 
  • NKX019, a wholly owned program of Nkarta, is an investigational healthy donor-derived CAR NK cell therapy targeting CD19.
  • NKX019 is being investigated in an ongoing Phase 1 single-arm, open label, multi-center, international clinical trial that is designed to assess the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle monotherapy and combination therapy in patients with relapsed/refractory B cell malignancies.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.
  • By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting.

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022

These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of December 1, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of December 1, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune disease.
  • Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need.
  • For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn .

Leading National Prostate Cancer Nonprofit Spearheads Influential HHS Moonshot Meeting

Retrieved on: 
Friday, December 2, 2022

WASHINGTON, Dec. 2, 2022 /PRNewswire/ -- OCCASION: ZERO - The End of Prostate Cancer was invited to convene a White House discussion on prostate cancer as a part of the Biden administration's Cancer Moonshot Initiative. Launched in 2016, the Biden administration intends to reduce the national death rate from cancer by at least 50% over the next 25 years and improve the experience of people and their families living with and surviving cancer.

Key Points: 
  • WASHINGTON, Dec. 2, 2022 /PRNewswire/ -- OCCASION: ZERO - The End of Prostate Cancer was invited to convene a White House discussion on prostate cancer as a part of the Biden administration's Cancer Moonshot Initiative .
  • WHY: Over 3 million men are living with prostate cancer, making it the most commonly diagnosed cancer among American men.
  • Black men are almost twice as likely to be diagnosed with prostate cancer and over twice as likely to die from prostate cancer as White men.
  • ZERO The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted.

Press release - Deal on new rules to protect consumers from taking on too much debt

Retrieved on: 
Friday, December 2, 2022

On Friday morning, negotiators from Parliament and Council reached a provisional political agreement to update the EUs rules on consumer credit.

Key Points: 
  • On Friday morning, negotiators from Parliament and Council reached a provisional political agreement to update the EUs rules on consumer credit.
  • The new directive on consumer credits (CCD) aims to make the credit markets function smoothly while ensuring a high level of consumer protection.
  • According to the deal, the legislation will cover credit agreements of up to 100,000.
  • Consumers will have the right to early repayment and to reduce the total cost of their credit.

Publications - Study on farm certification schemes for sustainable agriculture - Committee on Agriculture and Rural Development

Retrieved on: 
Friday, December 2, 2022

Access to page content (press "Enter")

Key Points: 
  • Access to page content (press "Enter")
    Direct access to language menu (press "Enter")
    Direct access to search menu (press "Enter")
    EN - English
    BG -
    ES - espaol
    CS - etina
    DA - dansk
    DE - Deutsch
    ET - eesti keel
    EL -
    EN - English
    FR - franais
    GA - Gaeilge
    HR - hrvatski
    IT - italiano
    LV - latvieu valoda
    LT - lietuvi kalba
    HU - magyar
    MT - Malti
    NL - Nederlands
    PL - polski
    PT - portugus
    RO - romn
    SK - slovenina
    SL - slovenina
    FI - suomi
    SV - svenska
    News
    MEPs
    About Parliament
    Plenary
    Committees
    Delegations
    Other websites
    Other websites
    News
    MEPs
    About Parliament
    Plenary
    Committees
    Delegations
    Multimedia Centre
    Presidents website
    Secretariat-general
    Think tank
    EP Newshub
    At your service
    Visits
    Legislative train
    Contracts and Grants
    Register
    Committees
    European Parliament
    Search
    Search
    Please fill this field
    AGRI
    European Parliament
    Search
    Menu
    Choose your committee
    Choose your committee
    All committees - Homepage
    Foreign Affairs
    Human Rights
    Security and Defence
    Development
    International Trade
    Budgets
    Budgetary Control
    Economic and Monetary Affairs
    Tax Matters
    Employment and Social Affairs
    Environment, Public Health and Food Safety
    Industry, Research and Energy
    Internal Market and Consumer Protection
    Transport and Tourism
    Regional Development
    Agriculture and Rural Development
    Fisheries
    Culture and Education
    Legal Affairs
    Civil Liberties, Justice and Home Affairs
    Constitutional Affairs
    Womens Rights and Gender Equality
    Petitions
    Beating Cancer
    COVID-19 pandemic: lessons learned and recommendations for the future
    Foreign interference in all democratic processes in the European Union, including disinformation (INGE 2)
    Foreign Interference in all Democratic Processes in the European Union, including Disinformation
    Artificial Intelligence in a Digital Age
    Protection of Animals during Transport
    Use of Pegasus and equivalent surveillance spyware
    Go to the page
    AGRI
    Home
    Highlights
    Members
    Press releases
    Newsletters
    Publications
    Meetings
    Meeting documents
    Webstreaming
    Votes
    Minutes
    Documents
    Latest documents
    Motions for Resolution
    Search
    Work in progress
    Events
    Hearings
    Workshops
    Meetings with National Parliaments
    European Citizens Initiatives
    Supporting analyses
    Latest documents
    Search
    Presentation
    About
    Go back
    AGRI
    Home
    Publications
    Study on farm certification schemes for sustainable agriculture
    Study on farm certification schemes for sustainable agriculture
    Share this page on Facebook
    Share this page on Twitter
    Share this page on LinkedIn
    Farm certification schemes for sustainable agriculture